Agilent Technologies has selected Fluor Corporation to expand its oligonucleotide therapeutics manufacturing facility in Colorado, USA. The unit will include state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction.
Texas/USA – Fluor Corporation has recently announced that its Advanced Technologies & Life Sciences business was selected by Agilent Technologies to expand its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado, just north of Denver. Fluor is supporting engineering and procurement as part of the project. The total project value is 725 million dollars.
“Speed to market is essential in the pharmaceutical industry,” said Juan Hernández, president of Fluor’s Advanced Technologies & Life Sciences business. “We will incorporate state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction. This enables us to fast-track the project so that Agilent can meet its global customers’ needs by getting products to market faster.”
Stay up to Date
Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability. The completed facility will provide for the synthesis, purification and lyophilization of Agilent’s custom nucleic acids therapeutics, also known as oligonucleotides or oligos.
Oligos are short deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules that serve as the active pharmaceutical ingredients for drugs targeting a growing number of diseases, including cancer, cardiovascular disease, and rare and infectious diseases. Construction is underway with completion expected by 2026.
Stand vom 23.03.2021
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.